全文获取类型
收费全文 | 2982篇 |
免费 | 313篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 51篇 |
妇产科学 | 90篇 |
基础医学 | 78篇 |
口腔科学 | 187篇 |
临床医学 | 991篇 |
内科学 | 653篇 |
皮肤病学 | 96篇 |
神经病学 | 81篇 |
特种医学 | 42篇 |
外国民族医学 | 2篇 |
外科学 | 247篇 |
综合类 | 2篇 |
一般理论 | 16篇 |
预防医学 | 374篇 |
眼科学 | 30篇 |
药学 | 234篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 42篇 |
2020年 | 43篇 |
2018年 | 60篇 |
2017年 | 83篇 |
2016年 | 82篇 |
2015年 | 100篇 |
2014年 | 109篇 |
2013年 | 158篇 |
2012年 | 42篇 |
2011年 | 38篇 |
2010年 | 107篇 |
2009年 | 109篇 |
2008年 | 50篇 |
2007年 | 43篇 |
2006年 | 41篇 |
2005年 | 28篇 |
2004年 | 28篇 |
2003年 | 28篇 |
2002年 | 24篇 |
2001年 | 39篇 |
2000年 | 34篇 |
1999年 | 73篇 |
1998年 | 99篇 |
1997年 | 148篇 |
1996年 | 158篇 |
1995年 | 104篇 |
1994年 | 112篇 |
1993年 | 106篇 |
1992年 | 98篇 |
1991年 | 90篇 |
1990年 | 94篇 |
1989年 | 59篇 |
1988年 | 66篇 |
1987年 | 59篇 |
1986年 | 74篇 |
1985年 | 48篇 |
1984年 | 45篇 |
1983年 | 39篇 |
1982年 | 44篇 |
1981年 | 32篇 |
1980年 | 38篇 |
1979年 | 23篇 |
1978年 | 30篇 |
1977年 | 31篇 |
1976年 | 29篇 |
1975年 | 22篇 |
1971年 | 22篇 |
1965年 | 17篇 |
1955年 | 17篇 |
1954年 | 17篇 |
排序方式: 共有3300条查询结果,搜索用时 140 毫秒
1.
Kuo-yi Jade Chang MHealthEc MHM BSc Lisa Lorraine Dillon MSpecEd BPsych Lil Deverell COMS PhD MEd GradDipO&M BEd Mei Ying Boon PhD BOptom FAAO Lisa Keay PhD MPH BOptom 《Clinical & experimental optometry》2020,103(4):434-448
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual. 相似文献
2.
3.
Reliable discrimination between sinus tachycardia (ST) and pathologic tachycardia has been a major problem for automatic implantable antitachycardia devices. In patients whose sinus response to activity is as rapid or faster than their pathologic tachycardia (rate crossover), these unsophisticated devices deliver the programmed tachycardia response to either the pathologic or sinus tachycardia. Over a one-year period, 50 Intermedics Intertach Model 262–12 antitachycardia pulse generators were implanted to evaluate the specificity of a new group of tachycardia recognition algorithms. Patients were subjected to exercise testing and noninvasive programmed stimulation to demonstrate the efficacy of this new approach. The five recognition algorithms tested were various combinations of the following criteria: high rate HR), sudden onset (SO), rate stability (RS), and sustained high rate (SHR). False positive rates (tachycardia response inappropriately triggered by ST) were as follows: HR (93%); HR + SO (3%); HR + RS (63%); HR + (RS or SHR) (87%); HR + HS + SO (8%). Pair-wise significance testing between HR only and HR + SO (p < 0.001), HR + RS (p = 0.01) and HR + SO + RS (p < 0.001), demonstrated a significant reduction in the rate of false positives through the use of the sudden onset and rate stability criteria in concert with the standard high rate criterion. 相似文献
4.
5.
Bulimia is a distinct diagnostic eating disorder with its most noted manifestation being the rapid ingestion of large quantities of food followed by its elimination through the mouth. Because of the dental implications of highly acidic stomach contents chronically being regurgitated, the dentist is in a unique position to help identify the patient with bulimia. Dental erosion is not only the most easily noted but also the most destructive of the many oral problems caused by bulimia. This report of case describes a preventive dental prosthesis that can be used by the patient with bulimia to protect those teeth that are most affected by dental erosion. The construction of the prosthesis is easily completed with materials in the dental office and provides a great service to the patient with bulimia. 相似文献
6.
7.
8.
TODD F. HEATHERTON LYNN T. KOZLOWSKI RICHARD C. FRECKER KARL-OLOV FAGERSTROM 《Addiction (Abingdon, England)》1991,86(9):1119-1127
We examine and refine the Fagerström Tolerance Questionnaire (FTQ; Fagerström, 1978). The relation between each FTQ item and biochemical measures of heaviness of smoking was examined in 254 smokers. We found that the nicotine rating item and the inhalation item were unrelated to any of our biochemical measures and these two items were primary contributors to psychometric deficiencies in the FTQ. We also found that a revised scoring of time to the first cigarette of the day (TTF) and number of cigarettes smoked per day (CPD) improved the scale. We present a revision of the FTQ: the Fagerström Test for Nicotine Dependence (FTND). 相似文献
9.
10.
BERNHARD FREY MICHAEL WUTTE RUDOLF BERGER CLEANTHIS IOANNIDES MARTIN HÜLSMANN BRIGITTE STANEK RICHARD PACKER 《Pacing and clinical electrophysiology : PACE》1995,18(1):152-158
To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease/dilated cardiomyopathy in 61/175 patients, left ventricular ejection fraction 14%± 5%, New York Heart Association Class IIl/IIIIV in 102/79/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirtyseven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninetynine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PGE1 for preand afterload reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 ± 9 months; patients who underwent staged therapy for 9 ±5 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died: 13 (52%) deaths occurred suddenly, and 12 (48%) deaths occurred due to progressive pump failure. Thus, patients who underwent staged therapy were at increased risk for sudden death (P = 0.01, relative risk 3.4, 95% confidence interval 1.2–9.7) but were at lower risk for death from pump failure (P = 0.009, relative risk 0.44, 95% confidence interval 0.22–0.84). In patients who underwent therapy with continuous outpatient PGE1 (n = 7) or dobutamine (n= 21), risk for sudden death (P = NS by log rank test) did not increase. In conclusion, staged therapy significantly reduced death from pump failure; however, patients who could be stabilized and considered too well for heart transplantation were at increased risk for sudden death. Thus, overall survival did not improve. Of note, outpatient dobutamine did not increase the risk for sudden death. 相似文献